Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 7/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | RRM2 | P31350 | 1/20 | 0.35 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29010822 | 0.87 | SLC7A5 (0.44) | SLC7A5 | |
| SCHEMBL5662708 | 0.87 | SLC7A5 (0.44) | SLC7A5 | |
| SCHEMBL5663456 | 0.87 | SLC7A5 (0.44) | SLC7A5 | |
| SCHEMBL2182252 | 0.85 | DPP4 (0.38) | MME | |
| SCHEMBL7405823 | 0.85 | DPP4 (0.43) | PTPN1BACE1CTSDBACE2 | |
| SCHEMBL16468562 | 0.83 | DPP4 (0.47) | BACE1CTSDGNPATBACE2 | |
| SCHEMBL2182137 | 0.83 | OPRD1 (0.38) | MMEPTPN1BACE1CTSDGNPAT | |
| SCHEMBL29870736 | 0.83 | MME (0.53) | MMESLC7A5BACE1GNPAT | |
| SCHEMBL2182485 | 0.83 | PTPN1 (0.39) | MMEPTPN1SLC7A5BACE1CTSD | |
| SCHEMBL31331981 | 0.82 | BACE1 (0.47) | PTPN1BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| EP-1874788-A1 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111783-A1 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-10-26 | — | — | WO | disclosed |
| CN-1254478-C | Derivatives of monosaccharides as well adhesion inhibitors | RANBAXY LAB LTD (IN) | 2006-05-03 | — | — | CN | disclosed |
| CN-1167707-C | 2,3-0-isopropylidene derivatives of monosaccharides as cell adhesive inhibitors | ʵ | 2004-09-22 | — | — | CN | disclosed |
| EP-1144425-B1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LAB LTD (IN) | 2004-06-16 | — | — | EP | disclosed |
| CN-1343213-A | 2,3-0-isopropylidene derivatives of monosaccharides as cell adhesive inhibitors | RANBAXY LAB LTD (IN) | 2002-04-03 | — | — | CN | disclosed |
| CN-1343212-A | Derivatives of monosaccharides as well adhesion inhibitors | RANBAXY LAB LTD (IN) | 2002-04-03 | — | — | CN | disclosed |
| US-6329344-B1 | UREA DERIVATIVE OF ALKYLENE DIOXYFURAN ETHERS | RANBAXY LABORATORIES LIMITED (IN) | 2001-12-11 | — | — | US | disclosed |
| EP-1144425-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042053-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | MME 87/4885PTPN1 2074/4885SLC7A5 419/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | MME 630/4885PTPN1 2369/4885SLC7A5 228/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | MME 630/4885PTPN1 2369/4885SLC7A5 228/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | MME 87/4885PTPN1 2074/4885SLC7A5 419/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | MME 29/4885PTPN1 2671/4885SLC7A5 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.